A carregar...
Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?
Clinical responses to anti-tumor monoclonal antibody (mAb) treatment have been regarded for many years only as a consequence of the ability of mAbs to destroy tumor cells by innate immune effector mechanisms. More recently, it has also been shown that anti-tumor antibodies can induce a long-lasting...
Na minha lista:
| Publicado no: | Front Immunol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5557783/ https://ncbi.nlm.nih.gov/pubmed/28855903 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2017.00950 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|